Trial results

A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

NCT07326111 on ClinicalTrials.gov · last registry update 2026-01-08

An unusually large phase 4: 198 participants, more than double the 72 typical for the stage. Due to report December 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

University of Bonn

Sponsor type

Other

Enrollment

198

Started

2025-12-09

Primary completion

2028-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS

Conditions studied

Polycystic Ovary Syndrome (PCOS) · Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.